Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in ...

Palliative care for diffuse large B-cell lymphoma has significantly improved over the past several years, but disparities ...

In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.

Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as ...

Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...

XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the ...

Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...